- $11.72m
- $11.67m
- $41.71m
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales
Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength
Brief: Biofrontera Q4 Revenue USD 17.1 Million
Brief: Biofrontera Announces FDA Filing Acceptance Of Supplemental New Drug Application For Ameluz® Pdt In Superficial Basal Cell Carcinoma
Brief: Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt
Brief: Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues Between $17.0 Million And $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Brief: Biofrontera Announces Data Base Locks For Two Clinical Studies Supporting Key Data And Regulatory Milestones
Brief: Biofrontera Completes Transfer Of Ameluz® And Rhodoled® FDA Approval
Brief: Biofrontera Inc. Announces Filing Of Supplemental New Drug Application
Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024
Brief: Biofrontera announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics for up to $10 Million
Brief: Biofrontera Inc. Closes Purchase of All Ameluz and RhodoLED US Assets from Biofrontera AG
Brief: Biofrontera Inc. Announces Last-Patient-Out In Phase 2B Study Of Ameluz® (Aminolevulinic Acid HCI) Topical Gel
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Biofrontera Q2 Revenue USD 9 Million
Biofrontera Inc expected to post a loss of 42 cents a share - Earnings Preview